Navigation Links
Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
Date:9/5/2012

AP financial measures, including operating and other expenses adjusted to exclude certain non-cash and non-recurring expenses. These measures are not in accordance with, or an alternative to generally accepted accounting principles, or GAAP, and may be different from non-GAAP financial measures used by other companies. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are employee related non-cash expenses and the net amount of the therapeutic discovery project tax grant. We believe the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators we use as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, we have also provided corresponding GAAP financial measures for comparative purposes. Reconciliation between certain GAAP and non-GAAP measures is provided below.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our corporate mission statement reads as follows: To build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
(Date:7/10/2014)... -- The U.S. Department of Health and Human Services (HHS) ... Case Medical Center Seidman Cancer Center totaling $4.7 million ... care for patients with complex cancer. ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... Voreloxin Demonstrates Promising Clinical Activity in Patients with ... Difficult-to-Treat ... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) presented data from three ... the Chemotherapy Foundation Symposium held in New York on November ...
... 5 Medarex, Inc.,(Nasdaq: MEDX ) today ... of,an undisclosed amount from its licensing partner, Centocor ... trial of CNTO 95, a fully human antibody,targeting ... The CNTO 95 human antibody was generated using ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 2Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 3Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 4Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 5Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors 2
(Date:7/12/2014)... The Passenger Information System market is estimated ... million by 2019, at an expected CAGR of 26.5% ... public transport infrastructure in North America is well developed ... every corner of the region. The growing ridership figures ... service providers are driving the North American Passenger Information ...
(Date:7/12/2014)... HealthDay Reporter SATURDAY, July 12, 2014 ... surgical technique used to grind up uterine growths and remove ... cancer to other parts of a woman,s body, U.S. health ... and Drug Administration also said that women who do undergo ... a written consent stating that they understand the potential risks, ...
(Date:7/12/2014)... July 12, 2014 The Security Analytics ... 2013 to $3,376.6 million by 2019, at an expected ... 2019. The challenges to counter the increasing number of ... of outdated cyber defense systems in organizations are enormous. ... and remodeling their existing architecture to develop better and ...
(Date:7/12/2014)... (HealthDay News) -- If you make exercise fun, you,ll eat ... experiment, 56 adults were led on a 1.4-mile walk and ... a scenic walk. The participants were given lunch after the ... outing ate 35 percent more chocolate pudding for dessert than ... In another experiment, 46 adults were given mid-afternoon snacks after ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of her right ... of his left side. Eating became a difficult task for them ... them enjoy eating again,” said an inventor, from Fayetteville, N.C. As ... PLATE (P C H PLATE). , The PATRICIA CAROL HALL PLATE ... for individuals who suffer from stroke, experience tremors or loss of ...
Breaking Medicine News(10 mins):Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Make Exercise Fun, Eat Less Afterwards 2
... COLUMBIA, Mo. Most people have witnessed otherwise intelligent ... intoxicated, but what specifically happens in the brain to ... effects on brain activity from the University of Missouri ... people when they are making a mistake, ultimately reducing ...
... September 1, 2011Scientists involved in DNA vaccine research are ... effective delivery systems and the development of more efficient ... Top investigators in the field recently discussed these and ... "DNA Vaccines: Building on Clinical Progress and Exploring New ...
... THURSDAY, Sept. 1 (HealthDay News) -- Most children need to get ... last year, the American Academy of Pediatrics says. The 2011-12 ... year,s vaccine, but a person,s immunity decreases by as much as ... it,s important for children to get another flu shot this year, ...
... --,Molecular signals from stem cells within the skin,s fatty layer ... to new treatments for baldness in people, researchers report. ... to talk to the dormant stem cells at the base ... hair to grow again," senior study author Valerie Horsley, an ...
... engineer? Sex hormones strongly influence people,s interests, which ... to psychologists. , "Our results provide strong support ... by working with things versus people," said Adriene ... Sheri A. Berenbaum, professor of psychology and pediatrics, ...
... THURSDAY, Sept. 1 (HealthDay News) -- The intensity of exercise, ... your chances of living a longer life, a new study ... that men with high levels of cycling intensity lived 5.3 ... longer, than men with low intensity. Among female cyclists, ...
Cached Medicine News:Health News:Alcohol dulls brain 'alarm' that monitors mistakes, MU study finds 2Health News:GEN reports on advances in DNA vaccine delivery and production 2Health News:Last Year's Flu Shot Won't Protect Kids This Season 2Health News:Mouse Study Could Give New Clues to Fighting Baldness 2Health News:Sex hormones impact career choices 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: